Pill Identifier App

Luvox Side Effects

Generic Name: fluvoxamine

Note: This page contains information about the side effects of fluvoxamine. Some of the dosage forms included on this document may not apply to the brand name Luvox.

Not all side effects for Luvox may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to fluvoxamine: oral capsule extended release, oral tablet

In addition to its needed effects, some unwanted effects may be caused by fluvoxamine (the active ingredient contained in Luvox). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking fluvoxamine:

Less common
  • Behavior, mood, or mental changes
  • trouble with breathing
  • trouble with urinating
  • twitching
  • Absence of or decrease in body movements
  • agitation
  • blurred vision
  • chills
  • clumsiness or unsteadiness
  • confusion
  • convulsions (seizures)
  • diarrhea
  • fever
  • inability to move the eyes
  • increase in body movements
  • menstrual changes
  • nosebleeds
  • overactive reflexes
  • poor coordination
  • red or irritated eyes
  • redness, tenderness, itching, burning, or peeling of the skin
  • restlessness
  • shivering
  • skin rash
  • sore throat
  • sweating
  • talking or acting with excitement you cannot control
  • trembling or shaking
  • unusual bruising
  • unusual, incomplete, or sudden body or facial movements
  • unusual secretion of milk (in females)
  • weakness

Some of the side effects that can occur with fluvoxamine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common
  • Change in sexual performance or desire
  • constipation
  • headache
  • trouble sleeping
  • unusual tiredness
Less common
  • Abdominal or stomach pain
  • change in sense of taste
  • decreased appetite
  • feeling of constant movement of self or surroundings
  • frequent urination
  • heartburn
  • increased sweating
  • unusual weight gain or loss

For Healthcare Professionals

Applies to fluvoxamine: oral capsule extended release, oral tablet


Gastrointestinal side effects have included nausea, which may be the most common adverse effect of fluvoxamine (the active ingredient contained in Luvox) and occurs in as many as 40% of treated patients. Other reported gastrointestinal side effects have included vomiting, diarrhea, constipation, dyspepsia, dry mouth, taste perversion, dysphagia, flatulence, and abdominal pain.[Ref]

A study of 26,005 antidepressant users has reported 3.6 times more upper GI bleeding episodes with the use of SSRIs relative to the population who did not receive antidepressant medications. Upper gastrointestinal tract bleeding was observed in 4.7 times more frequently in patients receiving fluvoxamine.[Ref]

Nervous system

Nearly all selective serotonin reuptake inhibitors, mixed serotonin/norepinephrine reuptake inhibitors, and tricyclic antidepressants cause sleep abnormalities to some extent. These antidepressants have marked dose-dependent effects on rapid eye movement (REM) sleep, causing reductions in the overall amount of REM sleep over the night and delays the first entry into REM sleep (increased REM sleep onset latency (ROL)), both in healthy subjects and depressed patients. The antidepressants that increase serotonin function appear to have the greatest effect on REM sleep. The reduction in REM sleep is greatest early in treatment, but gradually returns towards baseline during long-term therapy; however, ROL remains long. Following discontinuation of therapy the amount of REM sleep tends to rebound. Some of these drugs (i.e., bupropion, mirtazapine, nefazodone, trazodone, trimipramine) appear to have a modest or minimal effect on REM sleep.[Ref]

Central nervous system side effects including headache, somnolence, and insomnia have been reported in up to 22% of treated patients. Other reported nervous system side effects include fatigue, dizziness, sleep abnormalities, tremor, nervousness, anxiety, agitation, malaise, amnesia, and vertigo. Cases of serotonin syndrome, akathisia, dyskinesia, dystonia, tics, confusion, aggression, and seizures have also been reported.

A few case reports have implicated fluvoxamine in causing seizures. The manufacturer reports that, during premarketing testing, 0.2% of patients experienced convulsions.

One case report suggested fluvoxamine may have been associated with the development of the symptoms of Tourette's Syndrome in a patient treated for obsessive compulsive disorder.[Ref]


Psychiatric side effects including cases of hypomania and mania, apathy, indifference, disinhibition (without concurrent hypomania), hallucinations, paranoid, suicidal or antisocial ideation, abnormal thinking, and panic attacks have been reported.[Ref]

The reported association between antidepressant drug therapy in patients with various diagnoses and the development of suicidal ideation is controversial.[Ref]


Other side effects including insomnia, and abnormal dreaming have been reported.

One study, and several case reports, have suggested that fluvoxamine (the active ingredient contained in Luvox) treated patients may be subject to a serotonergic withdrawal syndrome characterized by headaches, dizziness, confusion, irritability, hypomania followed by aggression, nausea, poor appetite, chest tightness, low energy, and weakness.

In one retrospective chart review of 352 patients who were supervised during tapering and discontinuation from serotonin reuptake inhibitor therapy, dizziness, lethargy, paresthesia, nausea, vivid dreams, irritability, and lowered mood were the most common symptoms reported. Patients with at least on qualitatively new symptom were defined in the fluvoxamine group at a rate of 17.2%.[Ref]


General side effects including anorexia have been reported in approximately 2% to 6% of treated patients.[Ref]

A case report has suggested that fluvoxamine may promote weight loss as a result of increased resting metabolic rate.[Ref]


Cardiovascular side effects including palpitations, faintness, and tachycardia have been reported in patients treated with fluvoxamine (the active ingredient contained in Luvox) One case report found no effect on blood pressure, heart rate, or ECG in elderly patients.[Ref]


Dermatologic side effects including excessive sweating has been reported to occur with fluvoxamine (the active ingredient contained in Luvox) therapy. Six cases of alopecia (0.02%) have been reported. A single case report has suggested that fluvoxamine may provoke toxic epidermal necrolysis. In another case report, a 69- year- old woman developed tingling tender erythema and bilateral symmetric bullae on the back of her feet, fingers, intergluteal fold, and gluteal areas after taking fluvoxamine (50 mg daily) for 3 months. Following discontinuation of fluvoxamine and administration of steroids and antibiotics the lesions abated a week later.[Ref]


Genitourinary side effects including abnormal ejaculation, impotence, anorgasmia, and decreased libido have been reported to occur in treated patients. Urinary frequency and urinary retention have also been reported.[Ref]

One study has reported the incidence of sexual dysfunction at 35% (which is higher than previously reported).

One case report has suggested that cyproheptadine may be an effective treatment for fluvoxamine induced male anorgasmia.[Ref]


Respiratory side effects including rhinitis have been reported to occur in treated patients.[Ref]


Endocrine side effects have included one case report suggesting that fluvoxamine (the active ingredient contained in Luvox) may have been associated with the development of the syndrome of inappropriate secretion of antidiuretic hormone in an elderly patient.[Ref]


Musculoskeletal side effects including hip fracture have been reported. In one study using the healthcare data from the providence of Ontario, Canada reviewing 8,239 patients treated for hip fractures, the adjusted odds ratio for hip fracture was 2.4 for exposure to selective serotonin reuptake inhibitors (including fluoxetine, fluvoxamine (the active ingredient contained in Luvox) paroxetine, and sertraline), compared to participants who had no exposure to antidepressants.[Ref]


Hematologic side effects have included one case of fluvoxamine- induced bleeding. A case of epistaxis and ecchymoses has also been reported.[Ref]


Metabolic side effects including hyponatremia have been reported.[Ref]

Numerous cases of hyponatremia have been reported following treatment with a selective serotonin reuptake inhibitor (SSRI). Risk factors for the development of SSRI- associated hyponatremia including advanced age, female gender, concomitant use of diuretics, low body weight, and lower baseline serum sodium levels have been identified. Hyponatremia tends to develop within the first few weeks of treatment (range 3 to 120 days) and typically resolves within 2 weeks (range 48 hours to 6 weeks) after therapy has been discontinued with some patients requiring treatment. The proposed mechanism for the development of hyponatremia involves the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) via release of antidiuretic hormone.[Ref]


1. Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992): 48-53;disc. 53-4

2. Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994): 387-95

3. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64

4. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.

5. Arya DK, Szabadi E "Dyskinesia associated with fluvoxamine." J Clin Psychopharmacol 13 (1993): 365-6

6. Wils V "Extrapyramidal symptoms in a patient treated with fluvoxamine." J Neurol Neurosurg Psychiatry 55 (1992): 330-1

7. Fennig S, Fennig SN, Pato M, Weitzman A "Emergence of symptoms of Tourette's syndrome during fluvoxamine treatment of obsessive-compulsive disorder." Br J Psychiatry 164 (1994): 839-41

8. Chong SA "Fluvoxamine and akathisia." J Clin Psychopharmacol 16 (1996): 334-5

9. Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991): 433-5

10. Gill M, LoVecchio F, Selden B "Serotonin syndrome in a child after a single dose of fluvoxamine." Ann Emerg Med 33 (1999): 457-9

11. Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994): 78-9

12. Tourjman S, Fontaine R "Fluvoxamine can induce confusion in the elderly." J Clin Psychopharmacol 12 (1992): 293

13. Mullins ME, Horowitz BZ "Serotonin syndrome after a single dose of fluvoxamine." Ann Emerg Med 34 (1999): 806-7

14. Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000): 1276-8

15. Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993): 321

16. George MS, Trimble MR "Dystonic reaction associated with fluvoxamine." J Clin Psychopharmacol 13 (1993): 220-1

17. George MS, Trimble MR "A fluvoxamine-induced frontal lobe syndrome in a patient with comorbid Gilles de la Tourette's syndrome and obsessive compulsive disorder." J Clin Psychiatry 53 (1992): 379-80

18. Lebegue B "Survivable fluvoxamine overdose." Am J Psychiatry 147 (1990): 1689

19. Fux M, Taub M, Zohar J "Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors." Acta Psychiatr Scand 88 (1993): 235-7

20. Mann JJ, Kapur S "The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy]." Arch Gen Psychiatry 48 (1991): 1027-33

21. Glancy GD "Antisocial ideation and activities precipitated by the administration of SSRIs." Can J Psychiatry 38 (1993): 695

22. Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991): 1263-4

23. Hoehn-Saric R, Lipsey JR, McLeod DR "Apathy and indifference in patients on fluvoxamine and fluoxetine." J Clin Psychopharmacol 10 (1990): 343-5

24. Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991): 391-2

25. Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993): 1455-7

26. Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993): 689-90

27. Wilson S, Argyropoulos S "Antidepressants and sleep: a qualitative review of the literature." Drugs 65 (2005): 927-47

28. Szabadi E "Fluvoxamine withdrawal syndrome." Br J Psychiatry 160 (1992): 283-4

29. Black DW, Wesner R, Gabel J "The abrupt discontinuation of fluvoxamine in patients with panic disorder." J Clin Psychiatry 54 (1993): 146-9

30. Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988): 948-9

31. Mallya G, White K, Gunderson C "Is there a serotonergic withdrawal syndrome?." Biol Psychiatry 33 (1993): 851-2

32. Roos JC "Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine." Br J Clin Pharmacol 15 Suppl 3 (1983): s439-45

33. Laird LK, Lydiard RB, Morton WA, Steele TE, Kellner C, Thompson NM, Ballenger JC "Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients." J Clin Psychiatry 54 (1993): 224-8

34. Gautam M "Alopecia due to psychotropic medications." Ann Pharmacother 33 (1999): 631-7

35. Wolkenstein P, Revuz J, Diehl JL, Langeron O, Roupie E, Machet L "Toxic epidermal necrolysis after fluvoxamine." Lancet 342 (1993): 304-5

36. Ke CL, Chen CC, Lin CT, Chen GS, Chai CY, Cheng ST "Fluvoxamine-induced bullous eruption mimicking hand-foot syndrome and intertrigo-like eruption: rare cutaneous presentations and elusive pathogenesis." J Am Acad Dermatol 55 (2006): 355-6

37. Nafziger AN, Bertino JS, GossBley AI, Kashuba ADM "Sexual dysfunction on fluvoxamine therapy - Dr. Nafziger and colleagues reply." J Clin Psychiatry 61 (2000): 62-3

38. Dorevitch A, Davis H "Fluvoxamine-associated sexual dysfunction." Ann Pharmacother 28 (1994): 872-4

39. Arnott S, Nutt D "Successful treatment of fluvoxamine-induced anorgasmia by cyproheptadine." Br J Psychiatry 164 (1994): 838-9

40. Nafziger AN, Bertino JS, GossBley AI, Kashuba ADM "Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy." J Clin Psychiatry 60 (1999): 187-90

41. Rothschild AJ "Sexual side effects of antidepressants." J Clin Psychiatry 61 (2000): 28-36

42. Laird LK "Sexual dysfunction on fluvoxamine therapy." J Clin Psychiatry 61 (2000): 62

43. Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993): 62-3

44. Spigset O, hedenmalm K "Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions." Pharmacotherapy 17 (1997): 348-52

45. Liu B, Anderson G, Mittmann N, To Teresa, Axcell T, Shear N "Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people." Lancet 351 (1998): 1303-7

46. Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5

47. Jacob S, Spinler SA "Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults." Ann Pharmacother 40 (2006): 1618-22

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.